KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Sep 2025 value amounting to -$448.3 million.

  • Alnylam Pharmaceuticals' Cash from Financing Activities fell 536.33% to -$448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.5 million, marking a year-over-year decrease of 205.66%. This contributed to the annual value of $294.2 million for FY2024, which is 70.89% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Cash from Financing Activities stood at -$448.3 million, which was down 934.03% from $53.8 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Cash from Financing Activities peaked at $573.8 million during Q3 2021, and registered a low of -$448.3 million during Q3 2025.
  • For the 3-year period, Alnylam Pharmaceuticals' Cash from Financing Activities averaged around $10.5 million, with its median value being $44.1 million (2025).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Cash from Financing Activities spiked by 1,580.50% in 2021 and then plummeted by 536.33% in 2025.
  • Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Cash from Financing Activities stood at $292.3 million in 2021, then slumped by 78.30% to $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then fell by 20.98% to $31.0 million in 2024, then plummeted by 536.33% to -$448.3 million in 2025.
  • Its Cash from Financing Activities was -$448.3 million in Q3 2025, compared to $53.8 million in Q2 2025 and $44.1 million in Q1 2025.